Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expert perspectives on de-escalation of antiplatelet therapy - Beyond the guidelines: Insights from the cardiovascular research technologies 2026 meeting.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Transcatheter vs surgical aortic valve implantation: age vs lifetime perspective.

European heart journal·2026
Same author

On the Noninferiority of Tirzepatide: Insights From SURPASS-CVOT.

Journal of the American College of Cardiology·2026
Same author

Current Incidence and Modality of Young Aortic Valve Replacement in the United States.

Circulation·2026
Same author

Expert perspectives on tricuspid repair | replacement | medical therapy - Beyond the Guidelines: Insights from the cardiovascular research technologies 2026 meeting.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

M-TEER for Mitral Regurgitation: Does RESHAPE-HF2 Break the Tie or Muddy the Waters?

JACC. Cardiovascular interventions·2026

Related Experiment Videos

Rosiglitazone and cardiovascular risk.

Sanjay Kaul1, George A Diamond

  • 1Division of Cardiology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA. kaul@cshs.org

Current Atherosclerosis Reports
|August 19, 2008
PubMed
Summary

Rosiglitazone, a diabetes drug, may increase heart attack risk. However, evidence is inconclusive, and criticisms question the initial findings regarding cardiovascular safety.

Area of Science:

  • Cardiovascular medicine
  • Pharmacology
  • Clinical trial analysis

Background:

  • Rosiglitazone, a thiazolidinedione, is a widely prescribed medication for type 2 diabetes.
  • Previous meta-analyses suggested a potential link between rosiglitazone use and increased cardiovascular events.
  • Concerns have been raised regarding the methodology and conclusions of these prior analyses.

Purpose of the Study:

  • To critically evaluate the limitations of existing meta-analyses on rosiglitazone and cardiovascular risk.
  • To summarize current evidence regarding rosiglitazone's association with myocardial infarction and cardiovascular death.
  • To discuss implications for drug safety evaluation and provide clinical recommendations.

Main Methods:

  • Review and critique of a meta-analysis involving 42 clinical trials.

Related Experiment Videos

  • Synthesis of available scientific literature on rosiglitazone and cardiovascular outcomes.
  • Analysis of drug safety evaluation processes.

    • Main Results:

    • A meta-analysis indicated a 43% increased risk of myocardial infarction (P=0.03) and 64% increased risk of cardiovascular death (P=0.06) with rosiglitazone.
    • Significant criticisms challenge the validity of these findings.
    • The current body of evidence remains inconclusive regarding rosiglitazone's cardiovascular risks.

    Conclusions:

    • The data linking rosiglitazone to increased myocardial infarction and cardiovascular death in diabetic patients is inconclusive.
    • Further rigorous investigation is needed to definitively establish the cardiovascular safety profile of rosiglitazone.
    • Healthcare providers should consider the limitations of current evidence when prescribing rosiglitazone.